Top 200 #10 Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Class | Brand | Generic | Indication | Dose Form | Route | Adult Dose | Ped. Dose | MOA |
Antiretroviral Agent; Protease Inhibitor | Prezista | Darunavir | HIV Infection | Oral Susp: 100mg/ml; Oral Tablet: 75, 150, 400, 600, 800mg | Oral | Tx naive: 800mg with ritonavir 100mg QD with food; Tx experienced: 600mg with ritonavir 100mg BID | 3YO+: Tx with no darunavir resistance: darunavir 35mg/kg with ritonavir 7mg/kg QD; Tx with darunavir resistance: 20mg/kg with ritonavir 3mg/kg BID | HIV-1 protease inhibitor that prevents the cleavage of Gag and Gag-Pol polyprotein yielding immature, noninfectious virus |
Antirheumatic; Immune Modulator | Orencia | Abatacept | Juvenile idiopathic arthritis; RA (moderate to severe) | IV Powder for Soln: 250mg; SubQ Soln: 125mg/ml | IV, SubQ | SubQ: 125mg once weekly; IV: Initial dose, doses at week 2 and 4, then every 4 wk | 6YO+: IV dose varies based on weight, same interval as adult | CTLA-4 Ig – demonstrates anti-inflammatory effects by down regulating T cell activation |
Bile Acid Sequestrant; Phosphate Binder | Renvela | Sevelamer | End Stage Renal Disease( hyperphosphatemia) | Oral Powder for Susp: 0.8gm/packet, 2.4gm/packet;Oral Tablet: 800mg | Oral | Varies based on serum phosphorus level 800-1600mg TID w/ meals | N/A | Binds with phosphate molecules through ionic and hydrogen bonding and reduces phosphate absorption in the dietary tract, thereby lowering the serum phosphate concentration |
Cartilaginous Defect Repair Agent | Synvisc | Hyaluronate (Hylan Polymers A & B) | Osteoarthritis of knee | Inj. Soln: 8mg/ml | Intra-articularly | Inject 16mg(2mL) into the knee once weekly x 3 weeks | N/A 21YO+ | Derivative of the natural substance, hyaluronan, that lubricates and enables the joint to work properly |
Erythropoietic; Hematopoietic, Colony Stimulating Factor | Aranesp | Darbepoetin alfa | Anemia (due to chemotherapy or of chronic renal failure) | Inj. Soln: many strengths 10mcg/0.4ml – 500mcg/ml | SubQ, IV | once weekly dosing to every 3-week dosing | 1YO+: Varies, once weekly - every 2 weeks | Binds to progenitor stem cells stimulating the production/ differentiation of RBCs |
Erythropoietic; Hematopoietic, Colony Stimulating Factor | Epogen; Procrit | Erythropoietin (Epoetin Alfa) | Anemia (due to chemo, chronic renal failure, zidovudine ADR); surgical procedure | Inj. Soln: 2000, 3000, 4000, 10000, 20000, 40000 (Procit only) U/ml | SubQ, IV | 50-100 U/kg 3 times weekly; 40,000U/wk | Cancer patient 5YO+: 60,000 U/wk ; Dialysis pt 1MO+: 50U/kg 3x weekly | Stimulates the division and differentiation of committed erythroid progenitors in the bone marrow increasing RBC production |
Immunological Agent; Monoclonal Antibody | Herceptin | Trastuzumab | Breast cancer (HER2 overexpression); gastric cancer; malignant neoplasm of cardio-esophageal junction of stomach | IV Powder for Soln: 440mg | IV | BREAST CANCER(adjuvant Tx): 2-4mg/kg IV every 3 weeks; Breast cancer (metastatic): 2-4mg/kg/wk. GASTRIC CANCER: 6-8 mg/kg IV every 3 wks until disease progression. All are infused over 30-90 mins | N/A | Binds to extracellular domain of the HER2 protein which is overexpressed in 25-30% of primary breast cancers; inhibits the growth of tumor cells & mediates ADCC |
Monoclonal Antibody, Angiogenesis inhibitor, Vascular Endothelial Growth Factor (VEGF) inhibitor | Lucentis | Ranibizumab | Diabetic macular edema (DME); exudative age-related macular degeneration (AMD); macular retinal edema | Intraocular Soln: 0.3mg/0.05ml, 0.5mg/0.5ml | Intra-vitreal Injection | Dose varies 0.3-0.5 mg once a month | N/A | Inhibits the human VEGF-A by binding to its active forms thereby preventing ocular angiogenesis by VEGF-A |
Thyroid Supplement | Synthroid; Levoxyl; Levothroid; Unithroid; | Levothyroxine | Hypothyroidism; Myxedema coma; TSH suppression | IV Powder for Soln: 100, 200, 500mcg; Oral Tablet: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300mcg | Oral, IV | 1.7mcg/kg/day. Severe: 12.5-25mcg/day; TSH suppression: 2mcg/kg/day | Hypothyrodism: 0mo-12yo: 10-3 mcg/kg/day | T3 and T4 are thought to act by binding to thyroid receptor proteins attached to DNA, thus activating gene transcription and protein synthesis |
Thyroid Supplement | Cytomel | Liothyronine | Hypothyroidism; Myxedema coma; Thyroid suppression; Simple Goiter | Oral Tablet: 5, 25, 50mcg IV Soln: 10mcg/mL | Oral, IV | Hypothyroidism: 25-75mcg/day; Myxedema; 50-100mcg/day | few months old: 20mcg/day; 1yo: 50 mcg/day; 3yo+: adult dosage | Synthetic natural thyroid hormone that stimulates O2 consumption by most body tissues. This accelerates BMR, and metabolism of carbs, proteins, and lipids. |
Thyroid Supplement | Armour Thyroid | Levothyroxine/Liothyronine (Thyroid) | Hypothyroidism; Thyroid stimulating hormone suppression | Oral Tablet: 15, 30, 60, 90, 120, 180, 240, 300mg | Oral | Initial Dose: 15-30mg/day Maintenance: 60-120mg/day | 0mo-12yo+: 7.5-90mg/day | T3 and T4 are thought to act by binding to thyroid receptor proteins attached to DNA, thus activating gene transcription and protein synthesis |
Nonbarbiturate Hypnotic | Ambien; Ambien CR; Edluar; Intermezzo; Zolpimist | Zolpidem | Insomnia | Oral Tab: 5,10mg; ER Tab: 6.25,12.5mg; SL Tab: Edluar: 5, 10mg, Intermezzo: 1.75, 3.5mg; Oral Mist Spray: 5mg/0.1ml or 5mg/ACT; (AmbienPak:10mg/tab) | Oral, Sublingually | Intermezzo:1.75mg/women, 3.75 mg/men. Women: 5mg, 6.25 mg . Men: 10mg, 12.5 mg All are taken immediately before bedtime USE LOWEST DOSE POSSIBLE | N/A | Binds the benzodiazepine (BZ) receptor subunit of the GABA-A receptor complex |
Nonbarbiturate Hypnotic | Lunesta | Eszopiclone | Insomnia | Oral Tablet: 1, 2, 3mg | Oral | 1-3 mg immediately before bedtime; Max: 3mg | N/A | Believed to bind to or interact allosterically at the GABA-receptor complex domain |
Antibiotic, cyclic lipopeptide | Cubicin | Daptomycin | Bacteremia assoc. with intravascular line, bacteria due to S. aureus; infection of skin and/or subQ tissue; | IV Powder for Soln: 500mg | IV | skin infection: 4mg/kg/day x 7-14 days; Bacteremi(S.aureus): 6mg/kg/day x 2-6 wks; Bacteremia (MRSA): 6-8mg/kg/day | N/A | Binds to bacterial cell membranes and causes cell death by inducing rapid depolarization of the membrane potential, leading to disruption of DNA, RNA, and protein synthesis |
Antimetabolite; Antineoplastic Agent | Xeloda | Capecitabine | Colon cancer; metastatic breast cancer; metastatic colorectal cancer, Duke stage C colon cancer | Oral Tablet: 150, 500mg | Oral | 1250mg/m^2 BID x 2 wk, followed by 1 wk rest, then 3wk cycle (x total of 24 wks) | N/A | See Word Doc (too long) |
Antineoplastic Agent; Tyrosine Kinase Inhibitor | Gleevec | Imatinib Mesylate | Leukemia (various forms); dermatofibrosarcoma protuberans; GI stromal tumor; hypereosinophilic syndrome; myelodysplastic syndrome (with PDGFR); myeloproliferative disorder (with PDGFR); systemic mast cell disease | Oral Tablet: 100, 400mg | Oral | 100-600mg QD | 1YO+ 340mg/m^2 per day Max: 600mg/day | Inhibits the bcr-abl tyrosine kinase and thus suppresses proliferation and promotes apoptosis in bcr-abl positive cell lines and fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia |
Antiretroviral, Reverse Transcriptase Inhibitor | Atripla | Efavirenz/ Emtricitabine/ Tenofovir | HIV infection | Oral Tablet: 600/200/300mg | Oral | 1 tab QD on an empty stomach | 12YO+ and weigh 40kg: 1 tab QD on an empty stomach | See Word Doc (too long) |
Antiretroviral, Reverse Transcriptase Inhibitor | Truvada | Emtricitabine/ Tenofovir | HIV Infection; also prophylaxis | Oral Tablet: 200/300mg | Oral | 1 tab QD on an empty stomach | 12YO+ and weigh 35kg+: 1 tab QD on an empty stomach | See Word Doc (too long) |
Antiretroviral; Antiviral; Protease Inhibitor | Reyataz | Atazanavir | HIV Infection | Oral Capsule: 150, 200, 300mg Oral Packet: 50mg | Oral | Typical dose: 300mg with 100mg ritonavir QD w/ food Patients who can't tolerate ritonavir: 400mg QD w/ food | 3Mo+: Packet: 200-250mg with 80 mg ritonavir QD w/food 6yo+: Cap: 150-300mg with 100mg ritonavir QD w/food 13yo+: and can't tolerate ritonavir: 400mg QD w/food | Azapeptide HIV-1 protease inhibitor, prevents formation of mature virions by selectively inhibiting the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells |
Antiretroviral Agent; Integrase Inhibitor | Isentress | Raltegravir | HIV Infection | Oral Tab: 400mg Chewable Tab: 25, 100mg Oral Powder for Suspension: 100mg/packet | Oral | 400mg BID | 4wk-older and <25kg: Chewable: 75-150mg BID. Oral susp: 20-100mg BID >25kg: 400mg tab BID >25kg: chewable: 150-300mg BID | Inhibits viral DNA insertion into the host’s cellular genome; inhibits HIV-1 integrase inhibitor |
Created by:
scottamus123
Popular Pharmacology sets